Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Antonio Balestrieri is active.

Publication


Featured researches published by Antonio Balestrieri.


Clinical Endocrinology | 1999

Role of oestrogen in male sexual behaviour: insights from the natural model of aromatase deficiency

Cesare Carani; Vincenzo Rochira; Marco Faustini-Fustini; Antonio Balestrieri; Granata

In order to evaluate the role of oestrogens on human male sexual behaviour, the gender‐identity, psychosexual orientation and sexual activity of a man with a congenital lack of oestradiol resulting from an inactivating mutation of the aromatase P450 gene was investigated. The psychosexual and sexual behavioural evaluations were performed before and during testosterone treatment and before oestradiol treatment, during three phases of different dosages of oestradiol treatment.


Molecular and Cellular Endocrinology | 2002

Congenital estrogen deficiency in men: a new syndrome with different phenotypes; clinical and therapeutic implications in men.

Vincenzo Rochira; Antonio Balestrieri; Bruno Madeo; Antonio Spaggiari; Cesare Carani

The report focuses on the role of estrogens in human male, dealing with two human models of congenital estrogen deficiency: estrogen resistance and aromatase deficiency. Similarities and differences of clinical phenotypes of these models are described and progresses of estrogen treatment of aromatase-deficient men are reported. Finally, the putative use of estrogen in men and the use of aromatase inhibitors and antiestrogen for male disorders are discussed.


The Journal of Clinical Endocrinology and Metabolism | 2012

Screening of Cushing's Syndrome in Outpatients with Type 2 Diabetes: Results of a Prospective Multicentric Study in Italy

Massimo Terzolo; Giuseppe Reimondo; Iacopo Chiodini; Roberto Castello; Roberta Giordano; Enrica Ciccarelli; Paolo Limone; Claudio Crivellaro; Irma Martinelli; Marcella Montini; Olga Disoteo; Bruno Ambrosi; Roberto Lanzi; Maura Arosio; Sanzio Senni; Antonio Balestrieri; Erica Solaroli; Bruno Madeo; Raffaella De Giovanni; Felice Strollo; Rodolfo Battista; Alessandro Scorsone; Vito A. Giagulli; Daniela Collura; Aldo Scillitani; Renato Cozzi; Marco Faustini-Fustini; Anna Pia; Roberta Rinaldi; Barbara Allasino

CONTEXT Cushings syndrome may remain unrecognized among patients referred for metabolic syndrome; thus, a proactive screening has been suggested in certain patient populations with features of the disorder. However, conflicting data have been reported on the prevalence of Cushings syndrome in patients with type 2 diabetes. OBJECTIVE Our aim was to evaluate the prevalence of unsuspected Cushings syndrome among outpatients with type 2 diabetes. DESIGN AND SETTING This was a cross-sectional prospective study in 24 diabetes clinics across Italy. PATIENTS Between June 2006 and April 2008, 813 patients with known type 2 diabetes without clinically overt hypercortisolism were evaluated. Follow-up of the study was closed in September 2010. Patients were not selected for characteristics conferring a higher pretest probability of hypercortisolism. Patients underwent a first screening step with the 1-mg overnight dexamethasone suppression test. RESULTS Forty patients failed to suppress serum cortisol less than 5.0 μg/dl (138 nmol/liter) and underwent a standard 2-d, 2-mg dexamethasone suppression test, after which six patients (0.6% of the overall series) failed to suppress cortisol less than 1.8 μg/dl (50 nmol/liter), receiving a definitive diagnosis of Cushings syndrome that was adrenal dependent in five patients. Four patients were cured, being able to discontinue, or reduce, the glucose-lowering agents. CONCLUSIONS The present data do not support widespread screening of patients with type 2 diabetes for Cushings syndrome; however, the disorder is less rare than previously thought when considering epidemiology of type 2 diabetes. Our results support a case-finding approach in patients with uncontrolled diabetes and hypertension despite appropriate treatment.


Molecular and Cellular Endocrinology | 2001

Congenital estrogen deficiency: in search of the estrogen role in human male reproduction.

Vincenzo Rochira; Antonio Balestrieri; Bruno Madeo; Enrica Baraldi; Marco Faustini-Fustini; Antonio R. M. Granata; Cesare Carani

Recently, a remarkable progress has been made in our understanding about the role of sex steroids in male physiology. In this paper, we consider the clinical aspects of congenital estrogen deficiency - notably, estrogen resistance and aromatase deficiency - in men and we discuss both well-established and supposed estrogen roles in the human male reproductive function. These topics include the role of estrogens in the control of gonadotropin secretion, in male fertility determination and psychosexual behavior. Briefly, estrogens play a pivotal role in the control of serum gonadotropin concentrations in the human male. Furthermore, a possible role of estrogens on both human male fertility and sexuality has also been suggested by recent studies, even though the available data are far from being conclusive. Conversely, for what concern fertility and sexual behavior, a well-established effect of estrogens has been provided by recent studies on male rodents, which show impaired sexual behavior and fertility as a consequence of estrogen defect.


Molecular and Cellular Endocrinology | 2001

Role of estrogen on bone in the human male: insights from the natural models of congenital estrogen deficiency

Vincenzo Rochira; Antonio Balestrieri; Marco Faustini-Fustini; Cesare Carani

The reports of congenital estrogen deficiency - notably, estrogen resistance and aromatase deficiency - have completely changed our knowledge on the role of estrogen on bone in males. Particularly, the bone changes at puberty, which were classically considered androgen-dependent, are now considered to be induced at least in part by estrogen action. Clinical cases of congenital estrogen deficiency have clearly demonstrated that the role of estrogens in epiphyseal closure, skeletal proportions and bone mineralization is crucial not only in women but also in men. In addition progress have been made in the treatment of such a rare disease even though further studies are needed to a definitive understanding of this issue.


The Journal of Sexual Medicine | 2008

The Effects of Citalopram and Fluoxetine on Sexual Behavior in Healthy Men: Evidence of Delayed Ejaculation and Unaffected Sexual Desire. A Randomized, Placebo‐Controlled, Double‐Blind, Double‐Dummy, Parallel Group Study

Bruno Madeo; Paolo Bettica; Stefano Milleri; Antonio Balestrieri; Antonio R. M. Granata; Cesare Carani; Vincenzo Rochira

INTRODUCTION Selective serotonin reuptake inhibitors (SSRIs) are known to induce delayed orgasm and delayed ejaculation, while their effect on other aspects of sexual function, such as sexual motivation, arousal, and erectile function are unclear. AIM In order to evaluate the effect of chronic administration of two SSRIs, citalopram and fluoxetine, on normal sexual function, we studied the parameters of male sexual behavior, erectile function, and ejaculation on 48 healthy male volunteers, aged 29.5 +/- 4.9, in a randomized, placebo-controlled, double-blind, double-dummy study. Methods. The subjects were randomized to receive placebo (16 subjects), or fluoxetine (20 mg/day) (16 subjects) or citalopram (20 mg/day) for the first week, and 40 mg/day in the following 3 weeks (16 subjects). MAIN OUTCOME MEASURES Sexual function was investigated at the screening and at the end of the study by means of test of penile erection (TPE) and masturbation ejaculation latency time (MELT) performed during visual erotic stimulation, and at each visit by self-filled questionnaires (International Index Erectile Function [IIEF-15] and Golombock Rust Inventory of Sexual Satisfaction [GRISS]). RESULTS All the erectile parameters, evaluated by means of RigiScan Plus during TPE, were not significantly different when both fluoxetine and citalopram were compared with placebo. A delay in the ejaculation time was observed both during citalopram and during fluoxetine treatment when compared with placebo, reaching a statistical significance only with citalopram. During the treatment with citalopram and fluoxetine, the IIEF-15 score of all items decreased except for those items related to sexual desire; however, the scores were significantly lower only for the citalopram treatment. CONCLUSIONS The treatment with citalopram or with fluoxetine was confirmed to delay ejaculation, but was significant only for citalopram. Citalopram and fluoxetine did not affect sexual desire. Citalopram and fluoxetine did not directly affect penile erection as objectively assessed by RigiScan, although an impairment in the subjective assessment of erectile function was observed, but was significant only for citalopram, and it was thought to be a possible consequence of the delayed ejaculation perceived as a trouble.


Journal of Endocrinological Investigation | 2016

Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis

Fabio Vescini; R. Attanasio; Antonio Balestrieri; F. Bandeira; S. Bonadonna; V. Camozzi; S. Cassibba; R. Cesareo; Iacopo Chiodini; C. Maria Francucci; L. Gianotti; F. Grimaldi; R. Guglielmi; Bruno Madeo; C. Marcocci; A. Palermo; Alfredo Scillitani; E. Vignali; Vincenzo Rochira; M. Zini

Treatment of osteoporosis is aimed to prevent fragility fractures and to stabilize or increase bone mineral density. Several drugs with different efficacy and safety profiles are available. The long-term therapeutic strategy should be planned, and the initial treatment should be selected according to the individual site-specific fracture risk and the need to give the maximal protection when the fracture risk is highest (i.e. in the late life). The present consensus focused on the strategies for the treatment of postmenopausal osteoporosis taking into consideration all the drugs available for this purpose. A short revision of the literature about treatment of secondary osteoporosis due both to androgen deprivation therapy for prostate cancer and to aromatase inhibitors for breast cancer was also performed. Also premenopausal females and males with osteoporosis are frequently seen in endocrine settings. Finally particular attention was paid to the tailoring of treatment as well as to its duration.


The Journal of Sexual Medicine | 2015

Erectile Dysfunction Is Common among Men with Acromegaly and Is Associated with Morbidities Related to the Disease

Francesco Lotti; Vincenzo Rochira; Rosario Pivonello; Daniele Santi; Mariano Galdiero; Elisa Maseroli; Antonio Balestrieri; Marco Faustini-Fustini; Alessandro Peri; Alessandra Sforza; Annamaria Colao; Mario Maggi; Giovanni Corona

INTRODUCTION The prevalence of erectile dysfunction (ED) and its correlates in men with acromegaly has never been investigated. AIM The aim of this study was to evaluate sexual function in men with acromegaly. METHODS Multicenter-based, retrospective analysis of a nonselected series of 57 acromegalic subjects (mean age: 52.7 ± 14.2 years) was performed. Acromegalic subjects reporting ED (n = 24) were compared with matched ED patients without acromegaly or pituitary disease (controls), selected from a cohort of more than 4,000 subjects enrolled in the Florence Sexual Medicine and Andrology Unit. MAIN OUTCOME MEASURES Patients were interviewed using Structured Interview on Erectile Dysfunction (SIEDY) structured interview, a 13-item tool for the assessment of ED-related morbidities. Several clinical and biochemical parameters were taken. Penile color Doppler ultrasound (PCDU) was performed in a subgroup of 37 acromegalic subjects. RESULTS ED was reported by 42.1% of acromegalic subjects. After adjusting for age and testosterone, acromegalic subjects with ED had a higher prevalence of hypertension and more often reported an impairment of sleep-related erections and a longer smoking habit. Accordingly, acromegaly-associated ED was characterized by a higher organic component and worse PCDU parameters. No relationship between ED and testosterone levels or other acromegaly-related parameters was found. However, acromegalic subjects with severe ED reported a longer disease duration. In a case-control analysis, comparing acromegalic subjects with ED-matched controls free from acromegaly (1:5 ratio), acromegalic men had a worse ED problem and a higher organic component of ED, as derived from SIEDY score. In line with these data, acromegalic patients with ED had a higher prevalence of major adverse cardiovascular events history at enrollment and lower PCDU parameters. CONCLUSIONS Subjects with complicated acromegaly are at an increased risk of developing ED, especially those with cardiovascular morbidities. Our data suggest including a sexual function evaluation in routine acromegaly follow-up.


Journal of Andrology | 2008

21-hydroxylase deficiency and klinefelter syndrome in an adult man: striking a balance between androgen excess and insufficiency.

Antonio Balestrieri; Lucia Zirilli; Bruno Madeo; Elisa Pignatti; Giuseppina Rossi; Cesare Carani; Vincenzo Rochira

A. BALESTRIERI,* L. ZIRILLI,{ B. MADEO,{ E. PIGNATTI,{ G. ROSSI,{ C. CARANI,{ AND V. ROCHIRA{ From the *Department of Medicine, ASL Cesena, Ospedale M. Bufalini, Cesena, Italy, the Integrated Department of Medicine, Endocrinology, Metabolism, and Geriatrics, NOCSAE of Baggiovara, Chair of Endocrinology, University of Modena and Reggio Emilia, Modena, Italy; and the `Section of Pathology, Azienda Policlinico di Modena, Modena, Italy.


Journal of Endocrinological Investigation | 2003

Bilateral osteonecrosis of the femoral head in an adult man affected by congenital estrogen deficiency

Antonio Balestrieri; Bruno Madeo; Vincenzo Rochira; L. Baldini; Cesare Carani

Osteonecrosis of femoral head is related to different predisposing factors. The pathogenesis is not completely understood, but an ischemic impairment seems to be one of the major determinants of bone necrosis. The association of bilateral necrosis of femoral heads and congenital aromatase deficiency is here reported. The absence of estrogen activity, as well as the persistence of unfused epiphyses for a long period of life, may be involved in the determinism of bilateral necrosis of bone femoral heads. The possibility of development of bone necrosis in patients affected by congenital estrogen deficiency needs to be considered and magnetic resonance imaging can be a useful method for an early detection of this disease.

Collaboration


Dive into the Antonio Balestrieri's collaboration.

Top Co-Authors

Avatar

Vincenzo Rochira

University of Modena and Reggio Emilia

View shared research outputs
Top Co-Authors

Avatar

Cesare Carani

University of Modena and Reggio Emilia

View shared research outputs
Top Co-Authors

Avatar

Bruno Madeo

University of Modena and Reggio Emilia

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Lucia Zirilli

University of Modena and Reggio Emilia

View shared research outputs
Top Co-Authors

Avatar

Antonio R. M. Granata

University of Modena and Reggio Emilia

View shared research outputs
Top Co-Authors

Avatar

Daniele Santi

University of Modena and Reggio Emilia

View shared research outputs
Top Co-Authors

Avatar

A. Colao

University of Naples Federico II

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge